Version 1
: Received: 6 February 2023 / Approved: 27 February 2023 / Online: 27 February 2023 (01:53:06 CET)
How to cite:
Kieser, R.; Khan, S.; Bejar, N.; Kiss, D. The Dawning of a New Enterprise: RNA Therapeutics for the Skin. Preprints2023, 2023020429. https://doi.org/10.20944/preprints202302.0429.v1.
Kieser, R.; Khan, S.; Bejar, N.; Kiss, D. The Dawning of a New Enterprise: RNA Therapeutics for the Skin. Preprints 2023, 2023020429. https://doi.org/10.20944/preprints202302.0429.v1.
Cite as:
Kieser, R.; Khan, S.; Bejar, N.; Kiss, D. The Dawning of a New Enterprise: RNA Therapeutics for the Skin. Preprints2023, 2023020429. https://doi.org/10.20944/preprints202302.0429.v1.
Kieser, R.; Khan, S.; Bejar, N.; Kiss, D. The Dawning of a New Enterprise: RNA Therapeutics for the Skin. Preprints 2023, 2023020429. https://doi.org/10.20944/preprints202302.0429.v1.
Abstract
Despite being under development for decades, RNA therapeutics have only recently emerged as viable platform technologies. The COVID-19 mRNA vaccines have demonstrated the promise and power of the platform technology. In response, novel RNA drugs are entering clinical trials at an accelerating rate. As the skin is the largest and most accessible organ, it has always been a preferred target for drug discovery. This holds true for RNA therapies as well, and multiple candidate RNA-based drugs are currently in development for an array of skin conditions. In this mini review, we catalog the RNA therapies currently in clinical trials for different dermatological diseases. We summarize the main types of RNA-related drugs and use examples of drugs currently in development to illustrate their key mechanism of action.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
